Conférence mensuelle du 25 février 2025 ( reportée à une date ultérieure) : Phage Therapy in Pharma: Integrating Drug Development and Regulatory Pathways

Phage Therapy in Pharma: Integrating Drug Development and Regulatory Pathways

Résumé : Phage therapy is redefining the treatment landscape against drug-resistant bacteria, offering a targeted and innovative alternative to conventional antibiotics. This presentation explores the comprehensive drug development process—from discovery and preclinical studies through clinical trials and market entry—for phage-based therapeutics. In addition, it examines the regulatory challenges and evolving frameworks that govern the approval and deployment of these novel therapies in the pharmaceutical industry.

Dr. Angela Victoria, PhD

Dr. Angela Victoria is an accomplished expert in drug development and biotherapeutics with a strong focus on phage technology. With extensive experience bridging research innovation and clinical application, she has contributed significantly to advancing phage therapies within the pharmaceutical sector. Currently engaged with SGS, Angela plays a pivotal role in shaping regulatory strategies and fostering collaborations that streamline the development and approval process for next-generation antibacterial treatments.

Mardi 25 février  2025 à 16h Suivi d’un 5 à 7 bière et pizza

Endroit : Université de Montréal, Pavillon Jean-Coutu, Local S1-151

Langue: Anglais

Ce contenu a été mis à jour le 9 avril 2025 à 20:54.